Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.
about
Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisPharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholatePharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasisComparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelLiposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Optimizing efficacy of amphotericin B through nanomodification.High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyPharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celComparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.Hepatotoxicity of Antimycotics Used for Invasive Fungal Infections: In Vitro Results.Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
P2860
Q33980413-26BBF5E5-6A3E-467A-B7F2-C526CB6B0F22Q34113512-00A519CE-F2FF-46B8-B169-19C2AC9A6AE0Q34113525-3AFC667C-1736-45C7-9E21-AFD1F62F1962Q34352186-EBD7821C-145A-444F-875D-92F924C86397Q34565059-DBF78422-8B0A-4882-9A4C-388493BDAA1AQ34680675-9BA9D96A-D8D6-49D1-AED1-EDFA233D4AFBQ36868273-8C0A93AA-15DC-4F8C-99F2-9BA4E1D441C9Q36920328-637AC9FA-7068-4CE7-A937-C293A6E046D3Q37016279-CBF07823-AB21-4DE6-ACCB-408BAE06274EQ37333175-4E4AD353-3F36-4F0E-BF2B-FF4B7C45D596Q39473415-BCE2308F-9894-4DBB-8F99-422C4B08C064Q39954346-58B5F807-7852-4E6C-B3CA-86D126553F70Q40225550-450D375A-9DC4-4451-8C6E-128C2EE59930Q42217419-CD4B93AB-2497-4950-A504-B5061C34D2C1
P2860
Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Toxicological profile and phar ...... ion of amphotericin B in rats.
@ast
Toxicological profile and phar ...... ion of amphotericin B in rats.
@en
type
label
Toxicological profile and phar ...... ion of amphotericin B in rats.
@ast
Toxicological profile and phar ...... ion of amphotericin B in rats.
@en
prefLabel
Toxicological profile and phar ...... ion of amphotericin B in rats.
@ast
Toxicological profile and phar ...... ion of amphotericin B in rats.
@en
P2093
P2860
P1476
Toxicological profile and phar ...... ion of amphotericin B in rats.
@en
P2093
P2860
P304
P407
P577
1998-02-01T00:00:00Z